» Articles » PMID: 33503844

Recent Advances of Microbiome-Associated Metabolomics Profiling in Liver Disease: Principles, Mechanisms, and Applications

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jan 28
PMID 33503844
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Advances in high-throughput screening of metabolic stability in liver and gut microbiota are able to identify and quantify small-molecule metabolites (metabolome) in different cellular microenvironments that are closest to their phenotypes. Metagenomics and metabolomics are largely recognized to be the "-omics" disciplines for clinical therapeutic screening. Here, metabolomics activity screening in liver disease (LD) and gut microbiomes has significantly delivered the integration of metabolomics data (i.e., a set of endogenous metabolites) with metabolic pathways in cellular environments that can be tested for biological functions (i.e., phenotypes). A growing literature in LD and gut microbiomes reports the use of metabolites as therapeutic targets or biomarkers. Although growing evidence connects liver fibrosis, cirrhosis, and hepatocellular carcinoma, the genetic and metabolic factors are still mainly unknown. Herein, we reviewed proof-of-concept mechanisms for metabolomics-based LD and gut microbiotas' role from several studies (nuclear magnetic resonance, gas/lipid chromatography, spectroscopy coupled with mass spectrometry, and capillary electrophoresis). A deeper understanding of these axes is a prerequisite for optimizing therapeutic strategies to improve liver health.

Citing Articles

Non-targeted metabolomic study in plasma in rats with post-traumatic osteoarthritis model.

Han P, Li X, Zhang C, Liao C, Wang W, Li Y PLoS One. 2025; 20(3):e0315708.

PMID: 40073326 PMC: 11903037. DOI: 10.1371/journal.pone.0315708.


A critical review of microbiome-derived metabolic functions and translational research in liver diseases.

Ganesan R, Thirumurugan D, Vinayagam S, Kim D, Suk K, Iyer M Front Cell Infect Microbiol. 2025; 15:1488874.

PMID: 40066068 PMC: 11891185. DOI: 10.3389/fcimb.2025.1488874.


Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease.

Ganesan R, Gupta H, Jeong J, Sharma S, Won S, Oh K Hepatol Int. 2023; 18(2):486-499.

PMID: 37000389 DOI: 10.1007/s12072-023-10518-9.


Microbiome and Metabolomics in Liver Cancer: Scientific Technology.

Ganesan R, Yoon S, Suk K Int J Mol Sci. 2023; 24(1).

PMID: 36613980 PMC: 9820585. DOI: 10.3390/ijms24010537.


Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.

Hyun J, Kim S, Yoon S, Lee S, Jeong J, Gupta H Int J Mol Sci. 2022; 23(15).

PMID: 35955885 PMC: 9368757. DOI: 10.3390/ijms23158749.


References
1.
Tanaka N, Matsubara T, Krausz K, Patterson A, Gonzalez F . Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology. 2012; 56(1):118-29. PMC: 6371056. DOI: 10.1002/hep.25630. View

2.
Liu M, Xie H, Ma Y, Li H, Li C, Chen L . High Performance Liquid Chromatography and Metabolomics Analysis of Tannase Metabolism of Gallic Acid and Gallates in Tea Leaves. J Agric Food Chem. 2020; 68(17):4946-4954. DOI: 10.1021/acs.jafc.0c00513. View

3.
Zeng J, Huang X, Zhou L, Tan Y, Hu C, Wang X . Metabolomics Identifies Biomarker Pattern for Early Diagnosis of Hepatocellular Carcinoma: from Diethylnitrosamine Treated Rats to Patients. Sci Rep. 2015; 5:16101. PMC: 4630653. DOI: 10.1038/srep16101. View

4.
Duseja A . Staging of hepatocellular carcinoma. J Clin Exp Hepatol. 2015; 4(Suppl 3):S74-9. PMC: 4284240. DOI: 10.1016/j.jceh.2014.03.045. View

5.
Jiang L, Si Z, Li M, Zhao H, Fu Y, Xing Y . H NMR-based metabolomics study of liver damage induced by ginkgolic acid (15:1) in mice. J Pharm Biomed Anal. 2017; 136:44-54. DOI: 10.1016/j.jpba.2016.12.033. View